19 US IPOs planned for the week of Jun 23

The following IPOs are expected to price this week:

Adeptus Health (ADPT), which operates the largest freestanding emergency room network in the US, plans to raise $100 million by offering 4.9 million shares at a price range of $19.00 to $22.00. At the midpoint of the proposed range, Adeptus Health would command a market value of $424 million. Adeptus Health, which was founded in 2002, booked $121 million in sales over the last 12 months. The Lewisville, TX-based company plans to list on the NYSE under the symbol ADPT. Deutsche Bank, Goldman Sachs, Evercore Partners and Morgan Stanley are the joint bookrunners on the deal.

Ambrx (AMBX), a biotech developing protein therapeutics to deliver large molecule drugs, plans to raise $70 million by offering 5.4 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Ambrx would command a market value of $246 million. Ambrx, which was founded in 2003, booked $20 million in sales over the last 12 months. The La Jolla, CA-based company plans to list on the NASDAQ under the symbol AMBX. Stifel and Wells Fargo Securities are the joint bookrunners on the deal.

Amphastar Pharmaceuticals (AMPH), which produces difficult-to-manufacture injectable and inhalable drugs, plans to raise $81 million by offering 7.4 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Amphastar Pharmaceuticals would command a market value of $475 million. Amphastar Pharmaceuticals, which was founded in 1996, booked $223 million in sales over the last 12 months. The Rancho Cucamonga, CA-based company plans to list on the NASDAQ under the symbol AMPH. Jefferies & Co., BMO Capital Markets and Piper Jaffray are the joint bookrunners on the deal.

Garnero Group Acquisition (GGAC), a blank check company managed by Mario Garnero to acquire energy or biotech companies in Latin American, plans to raise $125 million by offering 12.5 million shares at a price of $10.00. At the midpoint of the proposed range, Garnero Group Acquisition would command a market value of $162 million. Garnero Group Acquisition was founded in 2014. The Sao Paulo, Brazil-based company plans to list on the NASDAQ under the symbol GGAC. EarlyBird Capital is the lead bookrunner on the deal.

GlobeImmune (GBIM), which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, plans to raise $25 million by offering 1.6 million shares at a price range of $15.00 to $17.00. At the midpoint of the proposed range, GlobeImmune would command a market value of $84 million. GlobeImmune, which was founded in 1995, booked $22 million in sales over the last 12 months. The Louisville, CO-based company plans to list on the NASDAQ under the symbol GBIM. Aegis Capital is the lead bookrunner on the deal. (Previously filed for an IPO in July 2012 but withdrew in October 2013.)

GoPro (GPRO), a leading producer of wearable HD action cameras, plans to raise $401 million by offering 17.8 million shares at a price range of $21.00 to $24.00. At the midpoint of the proposed range, GoPro would command a market value of $3.4 billion. GoPro, which was founded in 2004, booked $966 million in sales over the last 12 months. The San Mateo, CA-based company plans to list on the NASDAQ under the symbol GPRO. J.P. Morgan, Citi and Barclays are the joint bookrunners on the deal.

Imprivata (IMPR), which provides secure access management software for the health care industry, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Imprivata would command a market value of $387 million. Imprivata, which was founded in 2001, booked $76 million in sales over the last 12 months. The Lexington, MA-based company plans to list on the NYSE under the symbol IMPR. J.P. Morgan and Piper Jaffray are the joint bookrunners on the deal.

KineMed (KNMD), which develops biomarker tests that measure disease progression to improve commercial drugs, plans to raise $32 million by offering 4.5 million shares at a price range of $6.50 to $7.50. At the midpoint of the proposed range, KineMed would command a market value of $121 million. KineMed, which was founded in 2001, booked $7 million in sales over the last 12 months. The Emeryville, CA-based company plans to list on the NASDAQ under the symbol KNMD. Feltl and Company is the lead bookrunner on the deal.

Materialise (MTLS), which sells 3D printing software and custom medical and industrial products, plans to raise $104 million by offering 8.0 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Materialise would command a market value of $619 million. Materialise, which was founded in 1990, booked $97 million in sales over the last 12 months. The Leuven, Belgium-based company plans to list on the NASDAQ under the symbol MTLS. Piper Jaffray and Credit Suisse are the joint bookrunners on the deal.

Microlin Bio (MCLB), a diagnostic and therapeutics biotech focusing on microRNA and its role in oncology, plans to raise $30 million by offering 4.3 million shares at a price range of $6.50 to $7.50. At the midpoint of the proposed range, Microlin Bio would command a market value of $60 million. Microlin Bio, which was founded in 2013, booked $0 million in sales over the last 12 months. The New York, NY-based company plans to list on the NASDAQ under the symbol MCLB. Brean Capital and Summer Street Research Partners are the joint bookrunners on the deal.

Minerva Neurosciences (NERV), a clinical-stage biotech developing treatments for CNS diseases, plans to raise $60 million by offering 5.5 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Minerva Neurosciences would command a market value of $187 million. Minerva Neurosciences, which was founded in 2007, booked $0 million in sales over the last 12 months. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol NERV. Jefferies is the lead bookrunner on the deal.

MOKO Social Media (MOKO), which operates a U.S. social media mobile ad network and an Australian flash sale site, plans to raise $10 million by offering 1.2 million shares at a price range of $7.50 to $9.00. At the midpoint of the proposed range, MOKO Social Media would command a market value of $164 million. MOKO Social Media, which was founded in 2004, booked $6 million in sales over the last 12 months. The Sydney, Australia-based company plans to list on the NASDAQ under the symbol MOKO. Northland Securities is the lead bookrunner on the deal.

NextEra Energy Partners, LP (NEP), carved out of NextEra Energy to operate ten wind and solar energy projects, plans to raise $325 million by offering 16.3 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, NextEra Energy Partners, LP would command a market value of $1.9 billion. NextEra Energy Partners, LP, which was founded in 2014, booked $169 million in sales over the last 12 months. The Juno Beach, FL-based company plans to list on the NYSE under the symbol NEP. BofA Merrill Lynch, Goldman Sachs and Morgan Stanley are the joint bookrunners on the deal.

ServiceMaster Global Holdings (SERV), which provides pest control services and warranties on household appliances, plans to raise $700 million by offering 35.9 million shares at a price range of $18.00 to $21.00. At the midpoint of the proposed range, ServiceMaster Global Holdings would command a market value of $2.5 billion. ServiceMaster Global Holdings, which was founded in 1952, booked $2.3 billion in sales over the last 12 months. The Memphis, TN-based company plans to list on the NYSE under the symbol SERV. J.P. Morgan, Credit Suisse, Goldman Sachs and Morgan Stanley are the joint bookrunners on the deal.

Syndax Pharmaceuticals (SNDX), a late-stage biotech developing a novel therapy for treatment-resistant breast cancer, plans to raise $60 million by offering 4.3 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Syndax Pharmaceuticals would command a market value of $179 million. Syndax Pharmaceuticals was founded in 2005. The Waltham, MA-based company plans to list on the NASDAQ under the symbol SNDX. Deutsche Bank and Jefferies & Co. are the joint bookrunners on the deal.

Taggares Agriculture (TAG), which operates vineyards and apple orchards in the Pacific Northwest, plans to raise $46 million by offering 7.0 million shares at a price range of $6.00 to $7.00. At the midpoint of the proposed range, Taggares Agriculture would command a market value of $54 million. Taggares Agriculture, which was founded in 1979, booked $8 million in sales over the last 12 months. The Kennewick, WA-based company plans to list on the NASDAQ under the symbol TAG. Janney Montgomery Scott and Roth Capital are the joint bookrunners on the deal.

TCP International Holdings (TCPI), a global maker of LED lights and compact fluorescent lamps, plans to raise $100 million by offering 7.1 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, TCP International Holdings would command a market value of $411 million. TCP International Holdings, which was founded in 1993, booked $440 million in sales over the last 12 months. The Cham, Switzerland-based company plans to list on the NYSE under the symbol TCPI. Deutsche Bank and Piper Jaffray are the joint bookrunners on the deal. (Previously filed for a $100 million IPO in March 2012 but withdrew in November 2012.)

The Michaels Companies (MIK), the largest arts and crafts retailer in North America, plans to raise $500 million by offering 27.8 million shares at a price range of $17.00 to $19.00. At the midpoint of the proposed range, The Michaels Companies would command a market value of $3.8 billion. The Michaels Companies was founded in 1983. The Irving, TX-based company plans to list on the NASDAQ under the symbol MIK. J.P. Morgan, Goldman Sachs, Barclays and Deutsche Bank are the joint bookrunners on the deal.

Xunlei (XNET), which offers digital content acceleration and online video services in China, plans to raise $73 million by offering 7.3 million shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, Xunlei would command a market value of $721 million. Xunlei, which was founded in 2003, booked $175 million in sales over the last 12 months. The Shenzhen, China-based company plans to list on the NASDAQ under the symbol XNET. J.P. Morgan and Citi are the joint bookrunners on the deal. (Previously set terms for a $114 million IPO in July 2011 and withdrew that October.)

Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.

Last week, there were 10 IPO pricings. Kite Pharma (KITE), a biotech developing cancer immunotherapies with the National Cancer Institute, was the week's winner, ending up 71% from its IPO price.